Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | £26,136,008 | £17,183,597 | £25,872,080 | £23,102,366 |
| - Cash | £1,655,272 | £859,365 | £854,106 | £1,160,424 |
| + Debt | £6,193,299 | £2,093,299 | £4,893,927 | £7,427,967 |
| Enterprise Value | £30,674,035 | £18,417,531 | £29,911,901 | £29,369,909 |
| Revenue | £12,299,557 | £11,713,850 | £11,340,688 | £10,987,338 |
| % Growth | 5% | 3.3% | 3.2% | – |
| Gross Profit | £5,570,452 | £5,408,108 | £5,031,186 | £4,803,253 |
| % Margin | 45.3% | 46.2% | 44.4% | 43.7% |
| EBITDA | £2,606,611 | £2,952,621 | £2,260,978 | £2,386,147 |
| % Margin | 21.2% | 25.2% | 19.9% | 21.7% |
| Net Income | £1,829,812 | £1,680,570 | £1,478,628 | £1,364,518 |
| % Margin | 14.9% | 14.3% | 13% | 12.4% |
| EPS Diluted | 4.1 | 3.77 | 3.31 | 3.06 |
| % Growth | 8.8% | 13.9% | 8.2% | – |
| Operating Cash Flow | £1,037,632 | £1,697,119 | £1,765,748 | £2,131,026 |
| Capital Expenditures | -£1,317,498 | -£310,588 | -£620,942 | -£415,817 |
| Free Cash Flow | -£279,866 | £1,386,531 | £1,144,807 | £1,715,209 |